Home | Clinical Care | Research | Training | Division Activities

Education and Training:

B.S. with Honors, University of Wisconsin-Madison (2000)

M.D. with Honors in Research, University of Wisconsin School of Medicine & Public Health (2007)

Residency in Internal Medicine, University of Wisconsin Hospital & Clinics (2007-2010)

Fellowship in Hematology and Oncology, University of Washington and Fred Hutchinson Cancer Research Center (2010-2013)

Ryan Cassaday, MD
Assistant Professor, Division of Hematology
University of Washington School of Medicine
Assistant Member, Clinical Research Division
Fred Hutchinson Cancer Research Center

Office Address:
Seattle Cancer Care Alliance
825 Eastlake Ave E, Box 358081, Mailstop G6075
Seattle, WA 98109

Phone:        (206) 288-6744
Fax:              (206) 288-1130
E-mail:         cassaday@u.washington.edu


Acute lymphoblastic leukemia, B-cell non-Hodgkin lymphoma, Hodgkin lymphoma


Testing novel treatments and developing improved risk-stratification methods for adults with acute lymphoblastic leukemia. Studying radioimmunotherapy-based conditioning regimens for stem cell transplantation as treatment for adults with high-risk lymphoma.


Cassaday RD, Gopal AK. What is the role of transplantation for indolent lymphoma? In: Govindan R, ed. 2012 ASCO Educational Book. Alexandria, VA: American Society of Clinical Oncology; 494-500, 2012.

Cassaday RD, Gopal AK. Allogeneic hematopoietic cell transplantation in mantle cell lymphoma. Best Pract Res Clin Haematol. 25(2):165-74, Jun 2012.

Cassaday RD, Guthrie KA, Budde LE, Thompson L, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Palanca-Wessels MC, Philip M, Bensinger WI, Holmberg LA, Shustov A, Green DJ, Libby EN, Maloney DG, Gopal AK. Specific features identify patients with relapsed/refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 19(9):1403-6; Sept 2013.

Petrich AM, Gandhi M, Jovanovic B, Castillo J, Rajguru S, Shah KA, Whyman JA, Lansigan F, Hernandez-Ilizaliturri FJ, Lee LX, Barta SK, Melinamani S, Karmali R, Adeimy C, Smith S, Dalal N, Nabhan C, Peace D, Vose J, Evens A, Shah N, Fenske T, Zelenetz A, Landsburg DJ, Howlett C, Mato A, Reddy N, Handler C, Cohen J, Song K, Sun HL, Press OW, Cassaday RD, Li S, Sohani AR, Abramson JS. Impact of induction regimen and stem cell transplantation on outcomes in patients with double hit lymphoma: a large multicenter retrospective analysis. Blood. 2014 Oct 9;124(15):2354-61.

Cassaday RD, Storer BE, Sorror ML, Sandmaier BM, Guthrie KA, Maloney DG, Rajendran JG, Pagel JM, Flowers ME, Green DJ, Rezvani AR, Storb RF, Press OW, Gopal AK. Long-term outcomes of patients with persistent indolent B-cell malignancies undergoing nonmyeloablative allogeneic transplantation. Biol Blood Marrow Transplant. 2015 Feb;21(2):281-7.

Cassaday RD, Goy A, Advani S, Chawla P, Nachankar R, Gandhi M, Gopal AK. A phase II, single-arm, open-label, multicenter study to evaluate the efficacy and safety of P276-00, a cyclin-dependent kinase inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2015 Jul;15(7):392-7.

Graf SA, Stevenson PA, Holmberg LA, Till BG, Press OW, Chauncey TR, Smith SD, Philip M, Orozco JJ, Shustov AR, Green DJ, Libby EN, Bensinger WI, Pagel JM, Maloney DG, Zhou Y, Cassaday RD, Gopal AK. Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma. Ann Oncol. 2015 Nov;26(11):2323-8.

Cassaday RD, Stevenson PA, Gooley TA, Chauncey TR, Pagel JM, Rajendran J, Till BG, Philip M, Orozco JJ, Bensinger WI, Holmberg LA, Shustov AR, Green DJ, Smith SD, Libby EN, Maloney DG, Press OW, Gopal AK. High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma. Br J Haematol. 2015 Dec;171(5):788-97.

Cassaday RD, Potts DA, Stevenson PA, Bar M, Georges GE, Shustov AR, Sorror ML, Wood BL, Delaney C, Doney KC, Storb RF, Sandmaier BM. Evaluation of allogeneic transplantation in first or later minimal residual disease-negative remission following adult-inspired therapy for acute lymphoblastic leukemia. Leuk Lymphoma. 2016; in press.